PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Latanoprost - Glaucoma / ocular hypertension

PAD Profile : Latanoprost - Glaucoma / ocular hypertension Important

Keywords :
Intra-ocular pressure
Brand Names Include :
Xalatan, Lotacryn, Monoprost
Important Information :
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
22 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Primary care prescribers do not have the necessary equipment or skills to perform ocular pressure readings to make a diagnosis. The APC recomments that this product, when used for treatment of glaucoma, should be considered as BLUE.

Note; the branded product (Xalatan) was considered as BLACK at the PCN in May 2017.

01 April 2011
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Pending the imminent patent expiry of Xalatan, generic latanoprost will be the most cost effective prostaglandin analogue in primary and secondary care. Acute trust colleagues are requested to initiate patients on generic latanoprost as the first line prostaglandin analogue. Xalatan prescribing in primary care should be changed to generic.

Associated BNF Codes

11. Eye
11.06.00. Treatment of glaucoma
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More